カテゴリー： Market Monitor Global, 世界, 医療/バイオ

末期腎不全（ESRD）治療の世界市場見通し2023年-2029年

◆英語タイトル：End Stage Renal Disease (ESRD) Therapy Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが発行した調査報告書（MMG23JU4754）

◆商品コード：MMG23JU4754
◆発行会社（リサーチ会社）：Market Monitor Global
◆発行日：2023年6月（※2025年版があります。お問い合わせください。）
◆ページ数：104
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後2-3営業日）
◆調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
◆産業分野：医療機器＆消耗品

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,250 ⇒換算￥468,000	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD4,225 ⇒換算￥608,400	見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）	USD4,875 ⇒換算￥702,000	見積依頼/購入/質問フォーム

★Market Monitor Globalに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Global End Stage Renal Disease (ESRD) Therapy Market 調査レポートは次の情報を含め、グローバルにおけるの末期腎不全（ESRD）治療市場規模と予測を収録しています。・世界の末期腎不全（ESRD）治療市場：売上、2018年-2023年、2024年-2029年
・世界の末期腎不全（ESRD）治療市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の末期腎不全（ESRD）治療市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。アメリカ市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「血液透析」セグメントは今後6年間、000%の年平均成長率で2029年までに000Mドルに成長すると予測されています。

末期腎不全（ESRD）治療のグローバル主要企業は、Fresenius、 DaVita、 Baxter、 Nipro、 B. Braun、 Asahi Kasei、 Nikkiso、 WEGO、 Newsol、 Mayo Clinic、 Guangdong Biolight、 Medtronic、 Sanxin Medtec、 Jafron Biomedical、 SWS Hemodialysis Care、 Tianyi Medicalなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

マーケットモニターグローバル社は、末期腎不全（ESRD）治療のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別マーケット分析】

世界の末期腎不全（ESRD）治療市場：タイプ別、2018年-2023年、2024年-2029年
世界の末期腎不全（ESRD）治療市場：タイプ別市場シェア、2022年
・血液透析、腹膜透析、腎移植

世界の末期腎不全（ESRD）治療市場：用途別、2018年-2023年、2024年-2029年
世界の末期腎不全（ESRD）治療市場：用途別市場シェア、2022年
・病院、腎透析センター、在宅、その他

世界の末期腎不全（ESRD）治療市場：地域・国別、2018年-2023年、2024年-2029年
世界の末期腎不全（ESRD）治療市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競争分析】

また、当レポートは主要な参入企業の分析を提供します。
・主要企業における末期腎不全（ESRD）治療のグローバル売上、2018年-2023年
・主要企業における末期腎不全（ESRD）治療のグローバル売上シェア、2022年
・主要企業における末期腎不全（ESRD）治療のグローバル販売量、2018年-2023年
・主要企業における末期腎不全（ESRD）治療のグローバル販売量シェア、2022年

さらに、当レポートは主要企業の情報を提示します。
Fresenius、 DaVita、 Baxter、 Nipro、 B. Braun、 Asahi Kasei、 Nikkiso、 WEGO、 Newsol、 Mayo Clinic、 Guangdong Biolight、 Medtronic、 Sanxin Medtec、 Jafron Biomedical、 SWS Hemodialysis Care、 Tianyi Medical

*************************************************************

・調査・分析レポートの概要
末期腎不全（ESRD）治療市場の定義
市場セグメント
世界の末期腎不全（ESRD）治療市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の末期腎不全（ESRD）治療市場規模
世界の末期腎不全（ESRD）治療市場規模：2022年 VS 2029年
世界の末期腎不全（ESRD）治療市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの末期腎不全（ESRD）治療の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の末期腎不全（ESRD）治療製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：血液透析、腹膜透析、腎移植
末期腎不全（ESRD）治療のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：病院、腎透析センター、在宅、その他
末期腎不全（ESRD）治療の用途別グローバル売上・予測

・地域別市場分析
地域別末期腎不全（ESRD）治療市場規模 2022年と2029年
地域別末期腎不全（ESRD）治療売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業の情報（企業概要、事業概要、主要製品、売上、ニュースなど）
Fresenius、 DaVita、 Baxter、 Nipro、 B. Braun、 Asahi Kasei、 Nikkiso、 WEGO、 Newsol、 Mayo Clinic、 Guangdong Biolight、 Medtronic、 Sanxin Medtec、 Jafron Biomedical、 SWS Hemodialysis Care、 Tianyi Medical
...

End-stage renal failure, also known as end-stage renal disease (ESRD), is can be caused by an underlying health problem, often diabetes or high blood pressure. ESRD is the final, permanent stage of chronic kidney disease, where kidney function has declined to the point that the kidneys can no longer function on their own. When the kidneys can no longer filter the blood of waste and extra fluid, patients need dialysis or a kidney transplant to survive.
This report aims to provide a comprehensive presentation of the global market for End Stage Renal Disease (ESRD) Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding End Stage Renal Disease (ESRD) Therapy. This report contains market size and forecasts of End Stage Renal Disease (ESRD) Therapy in global, including the following market information:
Global End Stage Renal Disease (ESRD) Therapy Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global End Stage Renal Disease (ESRD) Therapy market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Hemodialysis Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of End Stage Renal Disease (ESRD) Therapy include Fresenius, DaVita, Baxter, Nipro, B. Braun, Asahi Kasei, Nikkiso, WEGO and Newsol, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the End Stage Renal Disease (ESRD) Therapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global End Stage Renal Disease (ESRD) Therapy Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global End Stage Renal Disease (ESRD) Therapy Market Segment Percentages, by Type, 2022 (%)
Hemodialysis
Peritoneal Dialysis
Kidney Transplantation
Global End Stage Renal Disease (ESRD) Therapy Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global End Stage Renal Disease (ESRD) Therapy Market Segment Percentages, by Application, 2022 (%)
Hospitals
Kidney Dialysis Centers
At Homes
Others
Global End Stage Renal Disease (ESRD) Therapy Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global End Stage Renal Disease (ESRD) Therapy Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies End Stage Renal Disease (ESRD) Therapy revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies End Stage Renal Disease (ESRD) Therapy revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Fresenius
DaVita
Baxter
Nipro
B. Braun
Asahi Kasei
Nikkiso
WEGO
Newsol
Mayo Clinic
Guangdong Biolight
Medtronic
Sanxin Medtec
Jafron Biomedical
SWS Hemodialysis Care
Tianyi Medical
Outline of Major Chapters:
Chapter 1: Introduces the definition of End Stage Renal Disease (ESRD) Therapy, market overview.
Chapter 2: Global End Stage Renal Disease (ESRD) Therapy market size in revenue.
Chapter 3: Detailed analysis of End Stage Renal Disease (ESRD) Therapy company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of End Stage Renal Disease (ESRD) Therapy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 End Stage Renal Disease (ESRD) Therapy Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global End Stage Renal Disease (ESRD) Therapy Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global End Stage Renal Disease (ESRD) Therapy Overall Market Size
2.1 Global End Stage Renal Disease (ESRD) Therapy Market Size: 2022 VS 2029
2.2 Global End Stage Renal Disease (ESRD) Therapy Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top End Stage Renal Disease (ESRD) Therapy Players in Global Market
3.2 Top Global End Stage Renal Disease (ESRD) Therapy Companies Ranked by Revenue
3.3 Global End Stage Renal Disease (ESRD) Therapy Revenue by Companies
3.4 Top 3 and Top 5 End Stage Renal Disease (ESRD) Therapy Companies in Global Market, by Revenue in 2022
3.5 Global Companies End Stage Renal Disease (ESRD) Therapy Product Type
3.6 Tier 1, Tier 2 and Tier 3 End Stage Renal Disease (ESRD) Therapy Players in Global Market
3.6.1 List of Global Tier 1 End Stage Renal Disease (ESRD) Therapy Companies
3.6.2 List of Global Tier 2 and Tier 3 End Stage Renal Disease (ESRD) Therapy Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global End Stage Renal Disease (ESRD) Therapy Market Size Markets, 2022 & 2029
4.1.2 Hemodialysis
4.1.3 Peritoneal Dialysis
4.1.4 Kidney Transplantation
4.2 By Type – Global End Stage Renal Disease (ESRD) Therapy Revenue & Forecasts
4.2.1 By Type – Global End Stage Renal Disease (ESRD) Therapy Revenue, 2018-2023
4.2.2 By Type – Global End Stage Renal Disease (ESRD) Therapy Revenue, 2024-2029
4.2.3 By Type – Global End Stage Renal Disease (ESRD) Therapy Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global End Stage Renal Disease (ESRD) Therapy Market Size, 2022 & 2029
5.1.2 Hospitals
5.1.3 Kidney Dialysis Centers
5.1.4 At Homes
5.1.5 Others
5.2 By Application – Global End Stage Renal Disease (ESRD) Therapy Revenue & Forecasts
5.2.1 By Application – Global End Stage Renal Disease (ESRD) Therapy Revenue, 2018-2023
5.2.2 By Application – Global End Stage Renal Disease (ESRD) Therapy Revenue, 2024-2029
5.2.3 By Application – Global End Stage Renal Disease (ESRD) Therapy Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global End Stage Renal Disease (ESRD) Therapy Market Size, 2022 & 2029
6.2 By Region – Global End Stage Renal Disease (ESRD) Therapy Revenue & Forecasts
6.2.1 By Region – Global End Stage Renal Disease (ESRD) Therapy Revenue, 2018-2023
6.2.2 By Region – Global End Stage Renal Disease (ESRD) Therapy Revenue, 2024-2029
6.2.3 By Region – Global End Stage Renal Disease (ESRD) Therapy Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America End Stage Renal Disease (ESRD) Therapy Revenue, 2018-2029
6.3.2 US End Stage Renal Disease (ESRD) Therapy Market Size, 2018-2029
6.3.3 Canada End Stage Renal Disease (ESRD) Therapy Market Size, 2018-2029
6.3.4 Mexico End Stage Renal Disease (ESRD) Therapy Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe End Stage Renal Disease (ESRD) Therapy Revenue, 2018-2029
6.4.2 Germany End Stage Renal Disease (ESRD) Therapy Market Size, 2018-2029
6.4.3 France End Stage Renal Disease (ESRD) Therapy Market Size, 2018-2029
6.4.4 U.K. End Stage Renal Disease (ESRD) Therapy Market Size, 2018-2029
6.4.5 Italy End Stage Renal Disease (ESRD) Therapy Market Size, 2018-2029
6.4.6 Russia End Stage Renal Disease (ESRD) Therapy Market Size, 2018-2029
6.4.7 Nordic Countries End Stage Renal Disease (ESRD) Therapy Market Size, 2018-2029
6.4.8 Benelux End Stage Renal Disease (ESRD) Therapy Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia End Stage Renal Disease (ESRD) Therapy Revenue, 2018-2029
6.5.2 China End Stage Renal Disease (ESRD) Therapy Market Size, 2018-2029
6.5.3 Japan End Stage Renal Disease (ESRD) Therapy Market Size, 2018-2029
6.5.4 South Korea End Stage Renal Disease (ESRD) Therapy Market Size, 2018-2029
6.5.5 Southeast Asia End Stage Renal Disease (ESRD) Therapy Market Size, 2018-2029
6.5.6 India End Stage Renal Disease (ESRD) Therapy Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America End Stage Renal Disease (ESRD) Therapy Revenue, 2018-2029
6.6.2 Brazil End Stage Renal Disease (ESRD) Therapy Market Size, 2018-2029
6.6.3 Argentina End Stage Renal Disease (ESRD) Therapy Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa End Stage Renal Disease (ESRD) Therapy Revenue, 2018-2029
6.7.2 Turkey End Stage Renal Disease (ESRD) Therapy Market Size, 2018-2029
6.7.3 Israel End Stage Renal Disease (ESRD) Therapy Market Size, 2018-2029
6.7.4 Saudi Arabia End Stage Renal Disease (ESRD) Therapy Market Size, 2018-2029
6.7.5 UAE End Stage Renal Disease (ESRD) Therapy Market Size, 2018-2029
7 End Stage Renal Disease (ESRD) Therapy Companies Profiles
7.1 Fresenius
7.1.1 Fresenius Company Summary
7.1.2 Fresenius Business Overview
7.1.3 Fresenius End Stage Renal Disease (ESRD) Therapy Major Product Offerings
7.1.4 Fresenius End Stage Renal Disease (ESRD) Therapy Revenue in Global Market (2018-2023)
7.1.5 Fresenius Key News & Latest Developments
7.2 DaVita
7.2.1 DaVita Company Summary
7.2.2 DaVita Business Overview
7.2.3 DaVita End Stage Renal Disease (ESRD) Therapy Major Product Offerings
7.2.4 DaVita End Stage Renal Disease (ESRD) Therapy Revenue in Global Market (2018-2023)
7.2.5 DaVita Key News & Latest Developments
7.3 Baxter
7.3.1 Baxter Company Summary
7.3.2 Baxter Business Overview
7.3.3 Baxter End Stage Renal Disease (ESRD) Therapy Major Product Offerings
7.3.4 Baxter End Stage Renal Disease (ESRD) Therapy Revenue in Global Market (2018-2023)
7.3.5 Baxter Key News & Latest Developments
7.4 Nipro
7.4.1 Nipro Company Summary
7.4.2 Nipro Business Overview
7.4.3 Nipro End Stage Renal Disease (ESRD) Therapy Major Product Offerings
7.4.4 Nipro End Stage Renal Disease (ESRD) Therapy Revenue in Global Market (2018-2023)
7.4.5 Nipro Key News & Latest Developments
7.5 B. Braun
7.5.1 B. Braun Company Summary
7.5.2 B. Braun Business Overview
7.5.3 B. Braun End Stage Renal Disease (ESRD) Therapy Major Product Offerings
7.5.4 B. Braun End Stage Renal Disease (ESRD) Therapy Revenue in Global Market (2018-2023)
7.5.5 B. Braun Key News & Latest Developments
7.6 Asahi Kasei
7.6.1 Asahi Kasei Company Summary
7.6.2 Asahi Kasei Business Overview
7.6.3 Asahi Kasei End Stage Renal Disease (ESRD) Therapy Major Product Offerings
7.6.4 Asahi Kasei End Stage Renal Disease (ESRD) Therapy Revenue in Global Market (2018-2023)
7.6.5 Asahi Kasei Key News & Latest Developments
7.7 Nikkiso
7.7.1 Nikkiso Company Summary
7.7.2 Nikkiso Business Overview
7.7.3 Nikkiso End Stage Renal Disease (ESRD) Therapy Major Product Offerings
7.7.4 Nikkiso End Stage Renal Disease (ESRD) Therapy Revenue in Global Market (2018-2023)
7.7.5 Nikkiso Key News & Latest Developments
7.8 WEGO
7.8.1 WEGO Company Summary
7.8.2 WEGO Business Overview
7.8.3 WEGO End Stage Renal Disease (ESRD) Therapy Major Product Offerings
7.8.4 WEGO End Stage Renal Disease (ESRD) Therapy Revenue in Global Market (2018-2023)
7.8.5 WEGO Key News & Latest Developments
7.9 Newsol
7.9.1 Newsol Company Summary
7.9.2 Newsol Business Overview
7.9.3 Newsol End Stage Renal Disease (ESRD) Therapy Major Product Offerings
7.9.4 Newsol End Stage Renal Disease (ESRD) Therapy Revenue in Global Market (2018-2023)
7.9.5 Newsol Key News & Latest Developments
7.10 Mayo Clinic
7.10.1 Mayo Clinic Company Summary
7.10.2 Mayo Clinic Business Overview
7.10.3 Mayo Clinic End Stage Renal Disease (ESRD) Therapy Major Product Offerings
7.10.4 Mayo Clinic End Stage Renal Disease (ESRD) Therapy Revenue in Global Market (2018-2023)
7.10.5 Mayo Clinic Key News & Latest Developments
7.11 Guangdong Biolight
7.11.1 Guangdong Biolight Company Summary
7.11.2 Guangdong Biolight Business Overview
7.11.3 Guangdong Biolight End Stage Renal Disease (ESRD) Therapy Major Product Offerings
7.11.4 Guangdong Biolight End Stage Renal Disease (ESRD) Therapy Revenue in Global Market (2018-2023)
7.11.5 Guangdong Biolight Key News & Latest Developments
7.12 Medtronic
7.12.1 Medtronic Company Summary
7.12.2 Medtronic Business Overview
7.12.3 Medtronic End Stage Renal Disease (ESRD) Therapy Major Product Offerings
7.12.4 Medtronic End Stage Renal Disease (ESRD) Therapy Revenue in Global Market (2018-2023)
7.12.5 Medtronic Key News & Latest Developments
7.13 Sanxin Medtec
7.13.1 Sanxin Medtec Company Summary
7.13.2 Sanxin Medtec Business Overview
7.13.3 Sanxin Medtec End Stage Renal Disease (ESRD) Therapy Major Product Offerings
7.13.4 Sanxin Medtec End Stage Renal Disease (ESRD) Therapy Revenue in Global Market (2018-2023)
7.13.5 Sanxin Medtec Key News & Latest Developments
7.14 Jafron Biomedical
7.14.1 Jafron Biomedical Company Summary
7.14.2 Jafron Biomedical Business Overview
7.14.3 Jafron Biomedical End Stage Renal Disease (ESRD) Therapy Major Product Offerings
7.14.4 Jafron Biomedical End Stage Renal Disease (ESRD) Therapy Revenue in Global Market (2018-2023)
7.14.5 Jafron Biomedical Key News & Latest Developments
7.15 SWS Hemodialysis Care
7.15.1 SWS Hemodialysis Care Company Summary
7.15.2 SWS Hemodialysis Care Business Overview
7.15.3 SWS Hemodialysis Care End Stage Renal Disease (ESRD) Therapy Major Product Offerings
7.15.4 SWS Hemodialysis Care End Stage Renal Disease (ESRD) Therapy Revenue in Global Market (2018-2023)
7.15.5 SWS Hemodialysis Care Key News & Latest Developments
7.16 Tianyi Medical
7.16.1 Tianyi Medical Company Summary
7.16.2 Tianyi Medical Business Overview
7.16.3 Tianyi Medical End Stage Renal Disease (ESRD) Therapy Major Product Offerings
7.16.4 Tianyi Medical End Stage Renal Disease (ESRD) Therapy Revenue in Global Market (2018-2023)
7.16.5 Tianyi Medical Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List of Tables
Table 1. End Stage Renal Disease (ESRD) Therapy Market Opportunities & Trends in Global Market
Table 2. End Stage Renal Disease (ESRD) Therapy Market Drivers in Global Market
Table 3. End Stage Renal Disease (ESRD) Therapy Market Restraints in Global Market
Table 4. Key Players of End Stage Renal Disease (ESRD) Therapy in Global Market
Table 5. Top End Stage Renal Disease (ESRD) Therapy Players in Global Market, Ranking by Revenue (2022)
Table 6. Global End Stage Renal Disease (ESRD) Therapy Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global End Stage Renal Disease (ESRD) Therapy Revenue Share by Companies, 2018-2023
Table 8. Global Companies End Stage Renal Disease (ESRD) Therapy Product Type
Table 9. List of Global Tier 1 End Stage Renal Disease (ESRD) Therapy Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 End Stage Renal Disease (ESRD) Therapy Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global End Stage Renal Disease (ESRD) Therapy Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - End Stage Renal Disease (ESRD) Therapy Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - End Stage Renal Disease (ESRD) Therapy Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application – Global End Stage Renal Disease (ESRD) Therapy Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - End Stage Renal Disease (ESRD) Therapy Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - End Stage Renal Disease (ESRD) Therapy Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region – Global End Stage Renal Disease (ESRD) Therapy Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global End Stage Renal Disease (ESRD) Therapy Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global End Stage Renal Disease (ESRD) Therapy Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America End Stage Renal Disease (ESRD) Therapy Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America End Stage Renal Disease (ESRD) Therapy Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe End Stage Renal Disease (ESRD) Therapy Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe End Stage Renal Disease (ESRD) Therapy Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia End Stage Renal Disease (ESRD) Therapy Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia End Stage Renal Disease (ESRD) Therapy Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America End Stage Renal Disease (ESRD) Therapy Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America End Stage Renal Disease (ESRD) Therapy Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa End Stage Renal Disease (ESRD) Therapy Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa End Stage Renal Disease (ESRD) Therapy Revenue, (US$, Mn), 2024-2029
Table 30. Fresenius Company Summary
Table 31. Fresenius End Stage Renal Disease (ESRD) Therapy Product Offerings
Table 32. Fresenius End Stage Renal Disease (ESRD) Therapy Revenue (US$, Mn) & (2018-2023)
Table 33. Fresenius Key News & Latest Developments
Table 34. DaVita Company Summary
Table 35. DaVita End Stage Renal Disease (ESRD) Therapy Product Offerings
Table 36. DaVita End Stage Renal Disease (ESRD) Therapy Revenue (US$, Mn) & (2018-2023)
Table 37. DaVita Key News & Latest Developments
Table 38. Baxter Company Summary
Table 39. Baxter End Stage Renal Disease (ESRD) Therapy Product Offerings
Table 40. Baxter End Stage Renal Disease (ESRD) Therapy Revenue (US$, Mn) & (2018-2023)
Table 41. Baxter Key News & Latest Developments
Table 42. Nipro Company Summary
Table 43. Nipro End Stage Renal Disease (ESRD) Therapy Product Offerings
Table 44. Nipro End Stage Renal Disease (ESRD) Therapy Revenue (US$, Mn) & (2018-2023)
Table 45. Nipro Key News & Latest Developments
Table 46. B. Braun Company Summary
Table 47. B. Braun End Stage Renal Disease (ESRD) Therapy Product Offerings
Table 48. B. Braun End Stage Renal Disease (ESRD) Therapy Revenue (US$, Mn) & (2018-2023)
Table 49. B. Braun Key News & Latest Developments
Table 50. Asahi Kasei Company Summary
Table 51. Asahi Kasei End Stage Renal Disease (ESRD) Therapy Product Offerings
Table 52. Asahi Kasei End Stage Renal Disease (ESRD) Therapy Revenue (US$, Mn) & (2018-2023)
Table 53. Asahi Kasei Key News & Latest Developments
Table 54. Nikkiso Company Summary
Table 55. Nikkiso End Stage Renal Disease (ESRD) Therapy Product Offerings
Table 56. Nikkiso End Stage Renal Disease (ESRD) Therapy Revenue (US$, Mn) & (2018-2023)
Table 57. Nikkiso Key News & Latest Developments
Table 58. WEGO Company Summary
Table 59. WEGO End Stage Renal Disease (ESRD) Therapy Product Offerings
Table 60. WEGO End Stage Renal Disease (ESRD) Therapy Revenue (US$, Mn) & (2018-2023)
Table 61. WEGO Key News & Latest Developments
Table 62. Newsol Company Summary
Table 63. Newsol End Stage Renal Disease (ESRD) Therapy Product Offerings
Table 64. Newsol End Stage Renal Disease (ESRD) Therapy Revenue (US$, Mn) & (2018-2023)
Table 65. Newsol Key News & Latest Developments
Table 66. Mayo Clinic Company Summary
Table 67. Mayo Clinic End Stage Renal Disease (ESRD) Therapy Product Offerings
Table 68. Mayo Clinic End Stage Renal Disease (ESRD) Therapy Revenue (US$, Mn) & (2018-2023)
Table 69. Mayo Clinic Key News & Latest Developments
Table 70. Guangdong Biolight Company Summary
Table 71. Guangdong Biolight End Stage Renal Disease (ESRD) Therapy Product Offerings
Table 72. Guangdong Biolight End Stage Renal Disease (ESRD) Therapy Revenue (US$, Mn) & (2018-2023)
Table 73. Guangdong Biolight Key News & Latest Developments
Table 74. Medtronic Company Summary
Table 75. Medtronic End Stage Renal Disease (ESRD) Therapy Product Offerings
Table 76. Medtronic End Stage Renal Disease (ESRD) Therapy Revenue (US$, Mn) & (2018-2023)
Table 77. Medtronic Key News & Latest Developments
Table 78. Sanxin Medtec Company Summary
Table 79. Sanxin Medtec End Stage Renal Disease (ESRD) Therapy Product Offerings
Table 80. Sanxin Medtec End Stage Renal Disease (ESRD) Therapy Revenue (US$, Mn) & (2018-2023)
Table 81. Sanxin Medtec Key News & Latest Developments
Table 82. Jafron Biomedical Company Summary
Table 83. Jafron Biomedical End Stage Renal Disease (ESRD) Therapy Product Offerings
Table 84. Jafron Biomedical End Stage Renal Disease (ESRD) Therapy Revenue (US$, Mn) & (2018-2023)
Table 85. Jafron Biomedical Key News & Latest Developments
Table 86. SWS Hemodialysis Care Company Summary
Table 87. SWS Hemodialysis Care End Stage Renal Disease (ESRD) Therapy Product Offerings
Table 88. SWS Hemodialysis Care End Stage Renal Disease (ESRD) Therapy Revenue (US$, Mn) & (2018-2023)
Table 89. SWS Hemodialysis Care Key News & Latest Developments
Table 90. Tianyi Medical Company Summary
Table 91. Tianyi Medical End Stage Renal Disease (ESRD) Therapy Product Offerings
Table 92. Tianyi Medical End Stage Renal Disease (ESRD) Therapy Revenue (US$, Mn) & (2018-2023)
Table 93. Tianyi Medical Key News & Latest Developments
List of Figures
Figure 1. End Stage Renal Disease (ESRD) Therapy Segment by Type in 2022
Figure 2. End Stage Renal Disease (ESRD) Therapy Segment by Application in 2022
Figure 3. Global End Stage Renal Disease (ESRD) Therapy Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global End Stage Renal Disease (ESRD) Therapy Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global End Stage Renal Disease (ESRD) Therapy Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by End Stage Renal Disease (ESRD) Therapy Revenue in 2022
Figure 8. By Type - Global End Stage Renal Disease (ESRD) Therapy Revenue Market Share, 2018-2029
Figure 9. By Application - Global End Stage Renal Disease (ESRD) Therapy Revenue Market Share, 2018-2029
Figure 10. By Type - Global End Stage Renal Disease (ESRD) Therapy Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global End Stage Renal Disease (ESRD) Therapy Revenue Market Share, 2018-2029
Figure 12. By Application - Global End Stage Renal Disease (ESRD) Therapy Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global End Stage Renal Disease (ESRD) Therapy Revenue Market Share, 2018-2029
Figure 14. By Region - Global End Stage Renal Disease (ESRD) Therapy Revenue Market Share, 2018-2029
Figure 15. By Country - North America End Stage Renal Disease (ESRD) Therapy Revenue Market Share, 2018-2029
Figure 16. US End Stage Renal Disease (ESRD) Therapy Revenue, (US$, Mn), 2018-2029
Figure 17. Canada End Stage Renal Disease (ESRD) Therapy Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico End Stage Renal Disease (ESRD) Therapy Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe End Stage Renal Disease (ESRD) Therapy Revenue Market Share, 2018-2029
Figure 20. Germany End Stage Renal Disease (ESRD) Therapy Revenue, (US$, Mn), 2018-2029
Figure 21. France End Stage Renal Disease (ESRD) Therapy Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. End Stage Renal Disease (ESRD) Therapy Revenue, (US$, Mn), 2018-2029
Figure 23. Italy End Stage Renal Disease (ESRD) Therapy Revenue, (US$, Mn), 2018-2029
Figure 24. Russia End Stage Renal Disease (ESRD) Therapy Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries End Stage Renal Disease (ESRD) Therapy Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux End Stage Renal Disease (ESRD) Therapy Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia End Stage Renal Disease (ESRD) Therapy Revenue Market Share, 2018-2029
Figure 28. China End Stage Renal Disease (ESRD) Therapy Revenue, (US$, Mn), 2018-2029
Figure 29. Japan End Stage Renal Disease (ESRD) Therapy Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea End Stage Renal Disease (ESRD) Therapy Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia End Stage Renal Disease (ESRD) Therapy Revenue, (US$, Mn), 2018-2029
Figure 32. India End Stage Renal Disease (ESRD) Therapy Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America End Stage Renal Disease (ESRD) Therapy Revenue Market Share, 2018-2029
Figure 34. Brazil End Stage Renal Disease (ESRD) Therapy Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina End Stage Renal Disease (ESRD) Therapy Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa End Stage Renal Disease (ESRD) Therapy Revenue Market Share, 2018-2029
Figure 37. Turkey End Stage Renal Disease (ESRD) Therapy Revenue, (US$, Mn), 2018-2029
Figure 38. Israel End Stage Renal Disease (ESRD) Therapy Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia End Stage Renal Disease (ESRD) Therapy Revenue, (US$, Mn), 2018-2029
Figure 40. UAE End Stage Renal Disease (ESRD) Therapy Revenue, (US$, Mn), 2018-2029
Figure 41. Fresenius End Stage Renal Disease (ESRD) Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. DaVita End Stage Renal Disease (ESRD) Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Baxter End Stage Renal Disease (ESRD) Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Nipro End Stage Renal Disease (ESRD) Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. B. Braun End Stage Renal Disease (ESRD) Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Asahi Kasei End Stage Renal Disease (ESRD) Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Nikkiso End Stage Renal Disease (ESRD) Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. WEGO End Stage Renal Disease (ESRD) Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Newsol End Stage Renal Disease (ESRD) Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Mayo Clinic End Stage Renal Disease (ESRD) Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Guangdong Biolight End Stage Renal Disease (ESRD) Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Medtronic End Stage Renal Disease (ESRD) Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 53. Sanxin Medtec End Stage Renal Disease (ESRD) Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 54. Jafron Biomedical End Stage Renal Disease (ESRD) Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 55. SWS Hemodialysis Care End Stage Renal Disease (ESRD) Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 56. Tianyi Medical End Stage Renal Disease (ESRD) Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)

※参考情報

末期腎不全（End Stage Renal Disease, ESRD）とは、腎臓が正常に機能しなくなり、体内の老廃物や余分な水分を排泄できなくなった状態を指します。これにより、患者は生命を維持するために特別な治療が必要となります。末期腎不全は通常、慢性腎疾患の最終段階として発生し、さまざまな原因によって引き起こされることが多いです。ここでは、末期腎不全の定義や特徴、治療の種類、用途、関連技術について詳述していきます。

末期腎不全は、腎臓の機能が慢性的に低下し、糸球体濾過率（GFR）が15 mL/min未満に達する状態を指します。この段階では、腎臓はもはや自分自身の機能を維持することができず、尿毒症や電解質異常、代謝性アシドーシスなどの多様な合併症を引き起こします。これに対処するためには、腎代替療法が必要になります。

末期腎不全の主な特徴として、まず一つは自覚症状の出現です。ほとんどの患者は、倦怠感、浮腫（むくみ）、高血圧、貧血、心不全などの症状を示します。さらに、尿量が減少し、尿の性状にも変化が見られることがあります。また、血液検査においては、尿素窒素（BUN）やクレアチニンの値が上昇し、電解質異常が認められることが一般的です。これらの症状は、腎臓が体内の老廃物を効果的に排泄できないことに直接関連しています。

治療方法としては、主に以下の三つの選択肢があります。まず一つ目は、透析療法です。透析には、血液透析と腹膜透析の二種類があります。血液透析は、体外に血液を取り出し、機械を用いて老廃物を除去した後、再び体内に戻す方法です。一般的には週に何度か、専用の医療機関で行う必要があります。対して、腹膜透析は、患者自身が腹腔内に透析液を注入し、腹膜を通じて老廃物を除去する方法です。この治療は自宅で行えるため、生活の質を保ちやすいという利点があります。

二つ目は、腎移植です。腎移植は、腎不全患者に健康な腎臓を移植して、再び正常な腎機能を回復させる方法です。移植後は、免疫抑制剤を使用する必要がありますが、長期的には透析療法に比べて生活の質が大きく向上する可能性があります。ただし、移植待機のためのドナーを探すことが非常に困難な場合が多く、多くの患者が長期間透析療法に依存せざるを得ない状況が続いています。

三つ目は、対症療法です。これは、腎不全に伴う合併症の軽減を目指す治療法です。たとえば、高血圧の管理や貧血の治療、骨代謝異常への対応が含まれます。これらの対症療法は、患者がより快適に生活を続けるために重要な役割を果たします。

このように、末期腎不全の治療にはいくつかの選択肢がありますが、患者の状態や希望に応じて最適な方法を選ぶことが重要です。また、医療者は、治療の選択において患者と十分なコミュニケーションを図り、個々の生活スタイルや価値観を尊重しながら支援することが求められます。治療にあたっては、多職種チームによるアプローチが効果的であり、腎臓専門医、看護師、栄養士、ソーシャルワーカーなどが一丸となって患者を支える体制が重要です。

また、末期腎不全に関連する技術も進歩しています。新しい透析装置の開発や、透析用薬剤の改良、さらには生体材料を用いた腎負担の少ない治療方法も研究が進められています。最近では、遺伝子治療や細胞治療といった新しいアプローチも模索されており、今後の治療における選択肢が拡がることが期待されています。

末期腎不全は、身体的、精神的、経済的にも大きな負担をもたらす疾患であり、患者にとって適切な治療を受けることが重要です。自己管理や定期的な医療受診を通じて、できるだけ健康的な生活を維持するための努力が必要です。医療者は患者に対して手厚いサポートを提供することで、より良い生活の質を確保できるよう努めることが求められています。

このように、末期腎不全は非常に複雑な疾患であり、その治療には多種多様なアプローチが存在します。医療の進歩とともに、今後はさらに効果的な治療法が確立されることが期待されます。各患者に最適な治療を提供するために、引き続き各種の研究や開発が進行することが望まれます。

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 末期腎不全（ESRD）治療の世界市場見通し2023年-2029年(End Stage Renal Disease (ESRD) Therapy Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

末期腎不全（ESRD）治療の世界市場見通し2023年-2029年

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp